

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Metis TechBio Co., Ltd.

剂泰科技(北京)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 7666)

**VOLUNTARY ANNOUNCEMENT
INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF
HANG SENG COMPOSITE INDEX**

This announcement is made by Metis TechBio Co., Ltd. (the “**Company**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Company about the latest development of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that, according to the results of the quarterly review of the Hang Seng Family of Indexes for the period ended June 30, 2026 announced by Hang Seng Indexes Company Limited on August 21, 2026, the Company has been selected and will be included as a constituent stock of the Hang Seng Composite Index with effect from September 7, 2026. For further details, please refer to the relevant index notice(s) published on the website of Hang Seng Indexes Company Limited (<https://www.hsi.com.hk>).

The Hang Seng Composite Index, as a comprehensive Hong Kong market benchmark, covers the top 95% of listed companies by cumulative market capitalisation on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). It serves as a broadly applicable benchmark for index funds, mutual funds, and investment performance evaluation. Upon inclusion as a constituent stock of the Hang Seng Composite Index, the H shares of the Company issued and listed on the Stock Exchange are expected to meet the inclusion criteria for trading via the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect. The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are channels for stock trading and investment between capital market investors in Hong Kong and the Chinese Mainland.

The Board is of the view that the inclusion as a constituent stock of the Hang Seng Composite Index reflects the high recognition by the international capital market of the Company's investment value and growth prospects, which is helpful to broaden the Shareholders' base and attract more long-term institutional investors, and enhance the trading liquidity of the Company's shares, and lay a solid foundation for the long-term development of the Company, resulting in enhancement in investment value and reputation of the Company in the capital market.

The Board would like to express its sincere gratitude to all our Shareholders, investors and partners for their long-term trust and support.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Metis TechBio Co., Ltd.

Tsai-Ta Lai

Chairman of the Board, executive Director and chief executive officer

Hong Kong, August 23, 2026

As of the date of this announcement, the Board comprises Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.